See the DrugPatentWatch profile for Dupixent
How Much Does a Dupixent Dose Cost?
The price of a Dupixent dose varies significantly depending on the dosage prescribed and the insurance coverage of the patient. For instance, a 200 mg vial can cost approximately $3,794, while a 300 mg vial may be around $4,600 [1]. These figures represent list prices and do not reflect the out-of-pocket cost for individuals.
What Factors Influence Dupixent's Out-of-Pocket Cost?
A patient's out-of-pocket expense for Dupixent is primarily determined by their health insurance plan. This includes the specific copay or coinsurance amount, any deductibles that must be met, and whether the medication is subject to prior authorization requirements. For those without insurance, or with high deductibles, the cost can be substantial.
Are There Programs to Help Reduce Dupixent Costs?
Yes, Sanofi, the manufacturer of Dupixent, offers a Dupixent MyWay program. This program provides support for eligible patients, which can include copay cards for commercially insured individuals, helping to lower their out-of-pocket expenses. Information on eligibility and program details is available through Sanofi's patient services [1].
What Is the Typical Dosing Schedule for Dupixent?
Dupixent dosing is tailored to the specific condition being treated. For conditions like atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSWNP), eosinophilic esophagitis (EoE), and prurigo nodularis, the initial starting dose is typically 600 mg (two 300 mg injections) given as two subcutaneous injections. This is followed by a maintenance dose of 300 mg every two weeks. In some cases, for atopic dermatitis and asthma, the maintenance dose can be increased to 300 mg every week if needed [1].
When Does Dupixent's Patent Exclusivity End?
Patent exclusivity for Dupixent is a complex issue involving multiple patents. DrugPatentWatch.com tracks these patents, indicating that various patents related to Dupixent are set to expire in the coming years. For example, some key patents are listed with expected expiry dates around 2035 [2]. The exact date when generic or biosimilar versions could enter the market depends on the specific patent expiry, any patent challenges, and regulatory approvals.
What Conditions Does Dupixent Treat?
Dupixent is approved for a range of moderate-to-severe inflammatory conditions. These include atopic dermatitis in adults and children, moderate-to-severe asthma in adults and children aged 6 years and older, and chronic rhinosinusitis with nasal polyps (CRSWNP) in adults [1]. It is also approved for eosinophilic esophagitis (EoE) in adults and children aged 12 years and older, and for prurigo nodularis in adults [1].
How Does Dupixent Work?
Dupixent targets specific pathways involved in inflammation. It is a monoclonal antibody that inhibits the signaling of two key proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13) [1]. These cytokines are central to the type 2 inflammation seen in the conditions it treats. By blocking their action, Dupixent helps to reduce inflammation, improve skin barrier function, and alleviate symptoms associated with these diseases.
---
Sources:
[1] Dupixent.com
[2] DrugPatentWatch.com